LANGHORNE, Pa.--(BUSINESS WIRE)--Nov 22, 2024-- Savara Inc . (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to four new employees. On November 20, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 80,000 shares of the Company’s common stock and restricted stock units (RSUs) covering an aggregate of 70,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees’ acceptance of employment with the Company. The options have an exercise price of $3.13 per share, the closing trading price of the Company's common stock on the NASDAQ Global Market on the grant date. Each option has a 10-year term and vests as to 1/16 th of the number of shares subject to the option on each quarterly anniversary of the employee’s first day of employment, subject to the employee’s continued employment on each such vesting date. The RSUs vest in full on the two-year anniversary of the employee’s first day of employment, subject to the employee’s continued employment on such vesting date. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is delivered via an investigational eFlow ® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com , X: @SavaraPharma , LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/ ). *MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. View source version on businesswire.com : https://www.businesswire.com/news/home/20241122399085/en/ CONTACT: Media and Investor Relations Contact Savara Inc. Temre Johnson, Executive Director, Corporate Affairs ir@savarapharma.com KEYWORD: PENNSYLVANIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: HEALTH OTHER HEALTH CLINICAL TRIALS GENERAL HEALTH PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Savara Inc. Copyright Business Wire 2024. PUB: 11/22/2024 04:05 PM/DISC: 11/22/2024 04:06 PM http://www.businesswire.com/news/home/20241122399085/enCAPE GIRARDEAU, Mo. (AP) — Rob Martin had 17 points in Southeast Missouri State's 88-39 victory against Westminster (MO) on Sunday night. Martin also contributed seven rebounds for the Redhawks (7-6). Braxton Stacker scored 16 points while going 7 of 11 (1 for 5 from 3-point range) and added five rebounds. Damarion Walkup went 5 of 11 from the field (4 for 10 from 3-point range) to finish with 14 points. The Blue Jays were led in scoring by Walker Gohring, who finished with 13 points. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .
Ultimately, the balance between passenger convenience and safety remains a crucial consideration for transportation authorities when formulating policies regarding the carriage of personal items on trains. While the allowance of small knives may serve practical purposes for certain passengers, it is essential to prioritize the overall safety and well-being of all individuals on board. By promoting a culture of security consciousness and implementing effective measures to prevent potential risks, railway operators can enhance passenger confidence and ensure a secure and comfortable travel experience for everyone.Xia Zhengyan's appointment as an independent director also reflects the Company's dedication to promoting diversity and inclusivity in its governance structure. As a female leader in the financial industry, Xia Zhengyan serves as an inspiration to aspiring professionals, showcasing the importance of gender diversity and equality in corporate leadership.The highly anticipated sequel to the blockbuster animated film "Nezha: Birth of the Demon Child" has been officially announced by the production team, scheduled for release on Lunar New Year 2025 under the title "Nezha 2: Trouble in the Sea." Following the immense success of its predecessor, which broke numerous box office records and garnered critical acclaim, all eyes are now on whether the sequel can continue the cinematic phenomenon surrounding the beloved mythological character.
Mashburn scores 18 as Temple beats Buffalo 91-71
In the face of another wave of Mycoplasma pneumoniae infections, it is essential to be vigilant and proactive in both prevention and treatment strategies. By practicing good hygiene, following prevention guidelines, and utilizing appropriate antibiotic management, we can reduce the impact of Mycoplasma pneumoniae outbreaks and protect our communities from the devastating effects of antibiotic resistance. Stay informed, stay safe, and together, we can overcome the challenges posed by this persistent pathogen.
VitaGraft KidneyTM quantifies the amount of DNA fragments in transplant patients' blood that originate from the donor organ, a key biomarker for assessing graft health. This process is commonly referred to as donor-derived cell-free DNA (dd-cfDNA) testing and is widely used in clinical practice today. In this latest study, Oncocyte's proprietary diagnostic dd-cfDNA test using digital PCR was able to diagnose antibody-mediated rejection (AMR) in kidney transplant recipients nearly a year ahead of standard protocols 1 . "We are excited to see our dd-cfDNA technology demonstrate strong predictive value for AMR, supporting clinicians in identifying AMR in patients sooner, thereby enhancing the opportunity for better outcomes,” said Oncocyte Chief Science Officer Dr. Ekkehard Schuetz. "The trial's results further validate dd-cfDNA as a critical biomarker that can bridge diagnostic gaps for transplant patients.” For further context, de-novo donor specific antibody (dnDSA) is a routine biomarker used in kidney transplant management. The appearance of dnDSA in a patient -- that is, the patient is found to be dnDSA-positive (dnDSA+) -- signals an increased risk of AMR. This latest study shows that compared to standard of care, VitaGraft Kidney can significantly reduce the time to diagnosis of AMR in dnDSA+ patients. It is also the first randomized interventional study to validate any dd-cfDNA technology as a rule-in test for biopsy in a high-risk population. Catching AMR early, when kidney graft loss can be minimized, is becoming increasingly important as physicians explore the use of drugs, including the anti-CD38 drugs felzartamab and daratumumab, to manage rejection. Monitoring with VitaGraft in this high-risk patient population could support early intervention with these new therapeutic options. Once patients are on therapy, monitoring for therapeutic efficacy is also important to manage potential unwanted side effects. Publications using VitaGraft to monitor for efficacy for both aforementioned drugs can be found in the New England Journal of Medicine and Transplant International . In addition, earlier this year, Oncocyte signed an agreement with a European biotechnology company to be the provider of dd-cfDNA testing for a Phase II clinical trial for a separate therapeutic in AMR. Oncocyte expects to submit for claims expansion to its payor, MolDX 2 , to support the use of VitaGraft for these high-risk patients in the clinic. If granted, it would expand the use case beyond the current for-cause claim, opening significant new revenue opportunities. In sum, this clinical trial provides compelling evidence for dd-cfDNA monitoring as a tool for enhancing early intervention and improving outcomes for patients at increased risk of transplant rejection. Oncocyte scientists and inventors of the technology, Dr. Schuetz, Julia Beck and Kirsten Bornemann-Kolatzki, co-authored the study, which was initiated by researchers at Charité - Universitätsmedizin Berlin under the leadership of Prof. Klemens Budde. The study was published in Nephrology Dialysis Transplantation: Oxford Academic and may be found by accessing this link. Additional study details: Highlighting potential for improved patient outcomes, as well as implications for broader clinical applications and future therapies The interventional randomized trial, conducted between June 2021 and July 2023, involved 40 kidney transplant recipients with dnDSA, assessing longitudinal dd-cfDNA monitoring as a guiding tool for diagnostic biopsy compared to standard clinical practices. Oncocyte's proprietary dd-cfDNA technology was able to detect the onset of AMR significantly earlier in patients by guiding the indication for biopsy (median time from inclusion to diagnosis: 2.8 months) compared to the control group using standard of care (14.5 months). As noted above, this early intervention could offer a valuable advantage in transplant care by enabling prompt treatment before irreversible damage occurs. "This study underscores the impact of dd-cfDNA as a critical biomarker for early AMR detection, providing healthcare teams with timely data enabling them to initiate treatments sooner," said Dr. Aylin Akifova, first author from Charité. This study also suggests that dd-cfDNA monitoring could also be instrumental in identifying subclinical AMR-a silent condition that, if undiagnosed, can lead to significant graft damage. Additionally, the findings come at a crucial time, as mentioned above, as promising new treatments, including CD38-targeted therapies, are showing unprecedented efficacy in treating AMR. Early diagnosis with dd-cfDNA could provide the earliest window for intervention, offering an advantage for patients suffering from AMR, a disease with historically very limited treatment options. "We congratulate Charité's research teams on these compelling findings, which further underscore our mission to empower clinicians with tools for precision diagnostics while also democratizing access to novel molecular diagnostic testing to improve patient outcomes,” said Josh Riggs, CEO of Oncocyte. "We look forward to expanding the clinical applications of dd-cfDNA technology and supporting transplant communities worldwide with our innovative diagnostic solutions.” About Oncocyte Oncocyte is a diagnostics technology company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraftTM is a clinical blood-based solid organ transplantation monitoring test. GraftAssureTM is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIOTM is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNITM is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/ . For more information about our products, please visit the following web pages: VitaGraft KidneyTM - https://oncocyte.com/vitagraft-kidney/ VitaGraft LiverTM - https://oncocyte.com/vitagraft-liver/ GraftAssureTM - https://oncocyte.com/graftassure/ DetermaIOTM - https://oncocyte.com/determa-io/ DetermaCNITM - https://oncocyte.com/determa-cni/ VitaGraftTM, GraftAssureTM, DetermaIOTM, and DetermaCNITM are trademarks of Oncocyte Corporation. CONTACT: Jeff Ramson PCG Advisory (646) 863-6893 [email protected] Forward-Looking Statements Any statements that are not historical fact (including but not limited to statements that contain words such as "will,” "believes,” "plans,” "anticipates,” "expects,” "estimates,” "may,” and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, the expectation that Oncocyte will submit for claims expansion to MolDX to support the use of VitaGraft for high-risk patients in the clinic, which may expand the use case and open significant new revenue opportunities, the company's anticipated expansion of clinical applications of dd-cfDNA technology, the company's goal to support transplant communities worldwide with its innovative diagnostic solutions, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte's third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients' use of any diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the "Risk Factors” and other cautionary statements found in Oncocyte's Securities and Exchange Commission (SEC) filings, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
President-elect Donald Trump said in an interview that aired on Sunday that he would act on his first day in office to pardon rioters involved in the Jan. 6, 2021 Capitol attack, further building expectations for a broad granting of clemency. "I'm going to be acting very quickly, first day," Trump said on NBC News' "Meet the Press with Kristen Welker" when asked when he planned to pardon his supporters who were charged in the attack aimed at overturning his 2020 election defeat. Trump told Welker that there could be "some exceptions" to his pardons if the individuals had acted "radical" or "crazy" during the assault, which left more than 140 police officers injured and led to several deaths. But Trump described the prosecutions of his supporters as inherently corrupt and did not rule out pardoning the more than 900 defendants who had already pleaded guilty, including those accused of acting violently in the attack. "I'm going to look at everything. We're going to look at individual cases," Trump said. The comments - Trump's most detailed on the issue of pardons since he defeated Vice President Kamala Harris in the Nov. 5 election - will likely add to already high expectations for broad action once Trump is sworn in to office on Jan. 20. "He continues to put out the public message closer and closer to what the J6 community is asking for, which is clemency for all of the January 6ers," Suzzanne Monk, a longtime advocate for defendants charged in the riot, told Reuters. Hopes among Jan. 6 defendants and their supporters for broad-based clemency have been growing over the past week after President Joe Biden pardoned his son Hunter, marking a reversal from his pledge not to interfere with his son's criminal cases. Biden said Hunter deserved a pardon because he was the victim of political persecution, an argument Trump will likely use to justify mass pardons. Some Biden critics said his decision would lessen the political cost for Trump. Kimberly Wehle, a professor at the University of Baltimore School of Law, said she was worried broad amnesty for Jan. 6 defendants would serve to wrongly incentivize the fomenting of unrest or even violence on behalf of a president. "The idea that he's going to reward people for violating the law on his behalf in connection with an attempt to overthrow legitimate election results... that's not precedented," said Wehle, author of a recent book on presidential pardon power. In what has been billed as America's largest-ever criminal investigation, at least 1,572 defendants have been charged in the Jan. 6 attack, with crimes ranging from unlawfully entering restricted grounds to seditious conspiracy and violent assault. Of that total, more than 1,251 have been convicted or pleaded guilty and 645 have been sentenced to prison, with punishments ranging from a few days to 22 years, according to the latest data from the Justice Department. John Pierce, a lawyer who has represented dozens of Jan. 6 defendants, urged Trump to issue a blanket pardon for all who were charged with participating in the riot. "I just don't know how you do it otherwise," he said, noting that it would be difficult to parse which conduct out of the scores of cases that have already worked their way through the legal system would merit a pardon. "I think you would see a lot of unhappy people in the January 6 community" if pardons were granted on a case-by-case basis, he said. In the NBC interview, Trump lamented those held for long periods of detention, saying they were being kept in "a filthy, disgusting place that shouldn't even be allowed to be open." He described them as being victims of a "very nasty system." Attorney Norm Pattis believes pardons should cover his clients, Zachary Rehl and Joseph Biggs, two former leaders of the Proud Boys militant group sentenced to 15 and 17 years in prison after a jury convicted them of seditious conspiracy. Pattis said Trump, in promoting the idea that the 2020 election had been stolen from him through widespread fraud - an assertion for which there is no evidence - prompted his clients to believe that they had to take drastic action. "He needs to own the fact that he created a tremendous sense of expectations with his claims about a stolen election, and people responded to him as President of the United States," Pattis said. "I would hope that he would pardon broadly." Pattis said it was unclear how Trump might draw a line excluding some defendants from clemency due to acts of violence. Jake Lang, a New York man who was charged with assaulting police officers and has been held in jail prior to trial, said he was hopeful he would be swept up in a blanket pardon. "I think on January 20, 2025 we are going to see a similar situation to Hunter Biden," Lang said in a phone interview. "Everybody's pardoned, full exoneration. Get them all out of prison and get this thing over with, so that we can start the national healing process."In a resolute move to maintain fairness and integrity within the gaming community, the overseas server of "Infinite Warmth" recently announced the banning of 83 accounts involved in cheating activities. This stringent action serves as a stern warning to players who attempt to gain an unfair advantage through dishonest means.
The concept of moderate easing refers to a gradual loosening of monetary policy by central banks in order to stimulate economic growth. This can take several forms, including lowering interest rates, increasing the money supply, or implementing other measures to make borrowing easier and more attractive for businesses and consumers.In conclusion, Fengtai District public rental housing offers a compelling living option for individuals and families seeking a comfortable, affordable, and convenient place to call home. With its modern facilities, convenient location, and reasonable rental prices, living in Fengtai District is an opportunity not to be missed. If you are looking to upgrade your living situation or simply want to save money on housing costs, consider applying for public rental housing in Fengtai District today. Don't miss out on this chance to secure your new home in one of Beijing's most sought-after districts!Search for UnitedHealthcare CEO's killer yields evidence, but few answers